AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate …
Sleeping Off Diabetic Retinopathy
Sharing results from a real-world single center study of patients with diabetic macular oedema (DMO) who wore a home-use sleep mask (Noctura 400) for 12 months PolyPhotonix, the manufacturer of the Noctura 400 – a treatment for diabetic retinopathy – recently completed a realworld study at an NHS hospital in the UK, which began in 2019. The study analyzed the …
New telemedicine approach may allow for remote treatment of DR
A novel telemedicine approach combining the high speed of 5G wireless networks and navigated retinal laser photocoagulation could allow treatment of diabetic retinopathy at a distance.